OraQuick® HCV Rapid Antibody Test - not proceeding

Anticipated publication date:

A single use, point-of-care test for the qualitative detection of antibodies to hepatitis C virus (HCV) in oral fluid, fingerstick whole blood, venipuncture whole blood, plasma and serum.
Anticipated publication date
Notification date
October 2010
Topic area
  • Diagnostic procedures
  • Digestive system
  • Infectious diseases

Provisional Schedule

Submission Date: TBC
Topic Selection: 16 December 2010
Draft guidance meeting TBC
Consultation opens: TBC
Consultation ends: TBC
Final guidance meeting: TBC

Project Team

Patient Involvement Lead: Laura Norburn
Analyst: Sarah Baggaley
Communications Lead: Tonya Gillis
Project manager:

Marlon Hope

Implementation Lead: Katie Worrall


  • If you would like to become a registered stakeholder in the development of guidance on this technology, please complete a stakeholder registration and confidentiality form (Word), and return to us at medtech@nice.org.uk.

    Registered stakeholders will be informed of key stages in the development of guidance including when documents go out to consultation or comment.


5 August 2011
NICE's assessment of this medical technology is suspended.
29 June 2011
NICE is unable to develop medical technology guidance on OraQuick HCV Rapid Antibody Test because the manufacturer has decided not to pursue a submission for evaluation to the Medical Technologies Evaluation Programme (MTEP). NICE will therefore not be developing guidance on this topic.
Get involved